Zoetis Inc. (NYSE:ZTS) Stock Holdings Reduced by Ostrum Asset Management

Ostrum Asset Management trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 12.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 208,903 shares of the company's stock after selling 30,225 shares during the quarter. Zoetis comprises 2.9% of Ostrum Asset Management's portfolio, making the stock its 12th largest position. Ostrum Asset Management's holdings in Zoetis were worth $34,037,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC boosted its holdings in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. boosted its stake in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares during the period. Murphy & Mullick Capital Management Corp bought a new position in Zoetis in the 4th quarter worth about $44,000. Asset Planning Inc bought a new stake in shares of Zoetis during the fourth quarter valued at approximately $58,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Zoetis during the fourth quarter worth approximately $59,000. Institutional investors own 92.80% of the company's stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock worth $312,254 over the last quarter. Corporate insiders own 0.16% of the company's stock.

Zoetis Trading Up 0.8 %

Shares of Zoetis stock traded up $1.28 on Friday, reaching $153.58. 3,543,283 shares of the company were exchanged, compared to its average volume of 2,520,479. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The firm has a market capitalization of $68.52 billion, a price-to-earnings ratio of 28.08, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a fifty day moving average price of $158.96 and a 200-day moving average price of $168.86.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. On average, analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.30%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is currently 36.56%.

Analysts Set New Price Targets

Several analysts have weighed in on ZTS shares. Stifel Nicolaus cut their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Piper Sandler raised their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Finally, StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $214.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.